Animal Models in Antiepileptic Drug Discovery

Animal models have been indispensable in the identification and optimisation of antiseizure therapies. Early paradigms such as the maximal electroshock seizure (MES) test and pentylenetetrazol (PTZ) challenge remain foundational for rapid assessment of acute anticonvulsant efficacy. Chronic models, including electrical and chemical kindling, replicate the gradual development of focal and generalised epilepsy, enabling evaluation of long-term seizure suppression and disease-modifying potential. More recently, genetic rodent lines and zebrafish mutants have provided mechanistic insight into channelopathies and synaptic dysfunctions underlying specific epilepsy syndromes. Models of pharmacoresistant epilepsy, induced by repeated subtherapeutic dosing or status epilepticus, have advanced our understanding of refractoriness and guided the search for compounds with novel targets. Combined with automated video-EEG monitoring, high-throughput behavioural phenotyping and in vivo neurochemical sampling, these systems form an integrated platform for driving antiepileptic drug discovery and translating preclinical findings into clinical strategies worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Animal Models in Antiepileptic Drug Discovery publication trend

The graph below shows the total number of articles in animal models in antiepileptic drug discovery across all publications each year (not limited to Nature Index journals).

Technical terms

Maximal electroshock seizure (MES) test: An acute model inducing tonic–clonic seizures via high-intensity electrical current.

Pentylenetetrazol (PTZ) challenge: A chemoconvulsant model triggering clonic seizures through GABA_A receptor antagonism.

Kindling: The process by which repeated subthreshold stimuli produce progressively more severe and spontaneous seizures.

Pharmacoresistance: The reduced responsiveness to multiple antiseizure medicines characteristic of refractory epilepsy.

Phenotypic screening: In vivo drug discovery based on observable seizure-related behaviours in animal models.

References

1. Perampanel’s forgiveness factor in a variable medication adherence paradigm in a rat model of chronic epilepsy. Journal of Translational Medicine (2023).
2. Evaluation of antiseizure drug efficacy and tolerability in the rat lamotrigine‐resistant amygdala kindling model. Epilepsia Open (2019).
3. Animal Models of Drug-Resistant Epilepsy as Tools for Deciphering the Cellular and Molecular Mechanisms of Pharmacoresistance and Discovering More Effective Treatments. Cells (2023).
4. Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti‐seizure medication. Epilepsia Open (2023).